0001562180-21-007738.txt : 20211216
0001562180-21-007738.hdr.sgml : 20211216
20211216210436
ACCESSION NUMBER: 0001562180-21-007738
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211214
FILED AS OF DATE: 20211216
DATE AS OF CHANGE: 20211216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stock Elyse
CENTRAL INDEX KEY: 0001785732
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38080
FILM NUMBER: 211499326
BUSINESS ADDRESS:
BUSINESS PHONE: (203) 404-0410
MAIL ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Biohaven Pharmaceutical Holding Co Ltd.
CENTRAL INDEX KEY: 0001689813
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: D8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
BUSINESS PHONE: 203-404-0410
MAIL ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2021-12-14
false
0001689813
Biohaven Pharmaceutical Holding Co Ltd.
BHVN
0001785732
Stock Elyse
C/O BIOHAVEN PHARMACEUTICALS, INC.
215 CHURCH STREET
NEW HAVEN
CT
06510
false
true
false
false
Chief Medical Officer
Common Shares
2021-12-14
4
M
false
3362.00
20.79
A
10829.00
D
Common Shares
2021-12-14
4
M
false
3577.00
10.82
A
14406.00
D
Common Shares
2021-12-14
4
S
false
6939.00
105.024
D
7467.00
D
Common Shares
2021-12-15
4
M
false
6996.00
20.79
A
14463.00
D
Common Shares
2021-12-15
4
M
false
14923.00
10.82
A
29386.00
D
Common Shares
2021-12-15
4
S
false
20330.00
105.4317
D
9056.00
D
Common Shares
2021-12-15
4
S
false
1589.00
106.1679
D
7467.00
D
Common Shares
2187.00
I
By Spouse
Employee Stock Option (Right to Buy)
20.79
2021-12-14
4
M
false
3362.00
0.00
D
2027-12-06
Common Shares
3362.00
18534.00
D
Employee Stock Option (Right to Buy)
10.82
2021-12-14
4
M
false
3577.00
0.00
D
2027-04-05
Common Shares
3577.00
14923.00
D
Employee Stock Option (Right to Buy)
20.79
2021-12-15
4
M
false
6996.00
0.00
D
2027-12-06
Common Shares
6996.00
11538.00
D
Employee Stock Option (Right to Buy)
10.82
2021-12-15
4
M
false
14923.00
0.00
D
2027-04-05
Common Shares
14923.00
0.00
D
These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.00 - $105.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.00 - $105.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.00 - $106.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
The shares underlying this option vested as to 25% of the shares on December 7, 2018, the grant date, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date.
The shares underlying this option vested as to 25% of the shares on April 6, 2017, the grant date, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date
/s/ Jim Engelhart, Attorney-in-Fact
2021-12-16